Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29605045 | 1.00 | GNRHR (0.74) | GNRHRKCNH2 | |
| Hydrochloric Acid SCHEMBL30174366 | 0.99 | GNRHR (0.73) | GNRHRKCNH2 | |
| Hydrochloric Acid SCHEMBL17092991 | 0.99 | GNRHR (0.73) | GNRHRKCNH2 | |
| SCHEMBL30461687 | 0.93 | GNRHR (0.73) | GNRHRKCNH2 | |
| SCHEMBL30461571 | 0.92 | GNRHR (0.69) | GNRHRKCNH2 | |
| Hydrochloric Acid SCHEMBL31418380 | 0.92 | GNRHR (0.63) | GNRHRKCNH2 | |
| SCHEMBL30461575 | 0.92 | GNRHR (0.68) | GNRHRKCNH2 | |
| SCHEMBL28490029 | 0.92 | GNRHR (0.68) | GNRHRKCNH2 | |
| SCHEMBL29385627 | 0.91 | GNRHR (0.61) | GNRHRKCNH2 | |
| SCHEMBL29966967 | 0.91 | GNRHR (0.76) | GNRHRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795178-B2 | Compositions of thienopyrimidine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-24 | — | — | US | claimed |
| US-11731983-B2 | Production method of thienopyrimidine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-22 | — | — | US | claimed |
| EP-4119564-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2023-01-18 | — | — | EP | claimed |
| US-20220204525-A1 | COMPOSITIONS OF THIENOPYRIMIDINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-06-30 | — | — | US | claimed |
| US-20220135585-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-05 | — | — | US | claimed |
| US-9758528-B2 | Production method of thienopyrimidine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-12 | — | — | US | claimed |
| US-20150266891-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | claimed |
| US-12325714-B2 | Compositions of thienopyrimidine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-10 | — | — | US | disclosed |
| US-20250051353-A1 | COMPOSITIONS OF THIENOPYRIMIDINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-13 | — | — | US | disclosed |
| US-12180224-B2 | Thienopyrimidine derivatives and production methods thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-12-31 | — | — | US | disclosed |
| US-11795178-B2 | Compositions of thienopyrimidine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-24 | — | — | US | disclosed |
| US-11795178-B2 | Compositions of thienopyrimidine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-24 | — | — | US | disclosed |
| US-11795178-B2 | Compositions of thienopyrimidine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-24 | — | — | US | disclosed |
| US-9758528-B2 | Production method of thienopyrimidine derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-09-12 | — | — | US | disclosed |
| US-20170210753-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20170210753-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20170210753-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-27 | — | — | US | disclosed |
| US-20150266891-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150266891-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150266891-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795178-B2 | Compositions of thienopyrimidine derivatives | GNRHR, KISS1R, MC4R | GNRHR 1/4885KCNH2 962/4885 |
| US-20250051353-A1 | COMPOSITIONS OF THIENOPYRIMIDINE DERIVATIVES | GNRHR, KISS1R, NR5A1 | GNRHR 1/4885KCNH2 1167/4885 |
| US-20220135585-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | GNRHR, KISS1R, NR5A1 | GNRHR 1/4885KCNH2 1265/4885 |
| US-20150266891-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | GNRHR, KISS1R, NR5A1 | GNRHR 1/4885KCNH2 1246/4885 |
| US-20220204525-A1 | COMPOSITIONS OF THIENOPYRIMIDINE DERIVATIVES | GNRHR, KISS1R, MC4R | GNRHR 1/4885KCNH2 962/4885 |
| US-12180224-B2 | Thienopyrimidine derivatives and production methods thereof | GNRHR, KISS1R, MC4R | GNRHR 1/4885KCNH2 1017/4885 |
| US-11731983-B2 | Production method of thienopyrimidine derivative | GNRHR, KISS1R, NR5A1 | GNRHR 1/4885KCNH2 1265/4885 |
| US-20170210753-A1 | PRODUCTION METHOD OF THIENOPYRIMIDINE DERIVATIVE | GNRHR, KISS1R, NR5A1 | GNRHR 1/4885KCNH2 1265/4885 |
| US-12325714-B2 | Compositions of thienopyrimidine derivatives | GNRHR, KISS1R, NR5A1 | GNRHR 1/4885KCNH2 1167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.